ASCA IGA SACCHAROMYCES CEREVISIAE

The ASCA IgA Saccharomyces cerevisiae test is a serological assay that detects Immunoglobulin A (IgA) antibodies directed against the yeast Saccharomyces cerevisiae. Performed on a serum sample collected at home by a trained phlebotomist, the test uses validated immunoassay methods in UAE‑certified laboratories to provide physician‑ready results that support clinical evaluation.

This test is most useful as an adjunct in the assessment of inflammatory bowel disease (IBD), particularly to support a diagnosis of Crohn’s disease versus ulcerative colitis, and in the evaluation of chronic unexplained gastrointestinal symptoms. Results should be interpreted alongside clinical findings, endoscopic imaging and other laboratory markers; factors such as IgA deficiency, recent immunoglobulin therapy or immunosuppression can affect accuracy, so discuss medications and medical history with your clinician prior to testing.

• Anti‑Saccharomyces cerevisiae (ASCA) IgA antibody
• ASCA IgA titre (quantitative)
• Qualitative interpretation (Positive / Negative)
• Reference range / cut‑off value
• Sample type: Serum (venous blood)

• Suspected Crohn’s disease or other inflammatory bowel disease
• Chronic unexplained diarrhoea, abdominal pain or weight loss
• To help differentiate Crohn’s disease from ulcerative colitis
• When serological support is needed alongside endoscopy and imaging
• Before or during evaluation for immunomodulatory therapy (consult physician)

• Home blood collection by trained phlebotomist for patient convenience
• Processed in UAE‑certified laboratories with validated immunoassays
• Fast, physician‑ready reporting to support clinical decision‑making
• Supports differential diagnosis between Crohn’s disease and UC
• Quantitative and qualitative results for clear interpretation

• At‑home venous blood collection (serum sample) by an approved phlebotomist
• No fasting required — normal medications may be continued unless advised
• Inform the phlebotomist and ordering physician of recent immunoglobulin therapy or current immunosuppression
• Provide Emirates ID and, if requested, a physician referral or test requisition